Cite

HARVARD Citation

    de Blank, P. et al. (2022). MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro-oncology. 24 (11), pp. 1845-1856. [Online]. 
  
Back to record